These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 27698942)

  • 1. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
    Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
    Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
    [No Abstract]   [Full Text] [Related]  

  • 2. Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.
    Bao X; Wang MW; Zhang YP; Zhang YJ
    Biomed Res Int; 2014; 2014():218578. PubMed ID: 24860813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
    Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
    BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
    He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
    PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors.
    Wu C; Yue X; Lang L; Kiesewetter DO; Li F; Zhu Z; Niu G; Chen X
    Theranostics; 2014; 4(5):546-55. PubMed ID: 24672585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.
    Guo J; Guo N; Lang L; Kiesewetter DO; Xie Q; Li Q; Eden HS; Niu G; Chen X
    J Nucl Med; 2014 Jan; 55(1):154-60. PubMed ID: 24232871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
    Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
    Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
    Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
    Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG.
    Cui Y; Liu H; Liang S; Zhang C; Cheng W; Hai W; Yin B; Wang D
    Oncotarget; 2016 May; 7(19):27243-54. PubMed ID: 27029065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice.
    Yang G; Nie P; Kong Y; Sun H; Hou G; Han J
    Tumour Biol; 2015 May; 36(5):3285-91. PubMed ID: 25501513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Provost C; Rozenblum-Beddok L; Nataf V; Merabtene F; Prignon A; Talbot JN
    Mol Imaging Biol; 2019 Apr; 21(2):297-305. PubMed ID: 29948641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
    Battle MR; Goggi JL; Allen L; Barnett J; Morrison MS
    J Nucl Med; 2011 Mar; 52(3):424-30. PubMed ID: 21321268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
    Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
    Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Comparison Study of (18)F-Alfatide and (18)F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model.
    Wei YC; Gao Y; Zhang J; Fu Z; Zheng J; Liu N; Hu X; Hou W; Yu J; Yuan S
    Sci Rep; 2016 Jun; 6():28757. PubMed ID: 27350554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison study of dynamic [
    Pan Y; Dang H; Zhou H; Fu H; Wu S; Liu H; Zhang J; Wang R; Tian Y; Xu B
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):208. PubMed ID: 38647690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Distribution Volume of
    Roy J; Kuo F; Basuli F; Williams MR; Wong K; Green MV; Seidel J; Adler SS; Xu B; Choyke PL; Jagoda EM
    Cancer Biother Radiopharm; 2019 May; 34(4):238-244. PubMed ID: 30767667
    [No Abstract]   [Full Text] [Related]  

  • 17. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
    Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
    Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET monitoring angiogenesis of infarcted myocardium after treatment with vascular endothelial growth factor and bone marrow mesenchymal stem cells.
    Cai M; Ren L; Yin X; Guo Z; Li Y; He T; Tang Y; Long T; Liu Y; Liu G; Zhang X; Hu S
    Amino Acids; 2016 Mar; 48(3):811-820. PubMed ID: 26592497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent imaging of vascularization and metabolism in a mouse model of paraganglioma under anti-angiogenic treatment.
    Facchin C; Perez-Liva M; Garofalakis A; Viel T; Certain A; Balvay D; Yoganathan T; Woszczyk J; De Sousa K; Sourdon J; Provost J; Tanter M; Lussey-Lepoutre C; Favier J; Tavitian B
    Theranostics; 2020; 10(8):3518-3532. PubMed ID: 32206105
    [No Abstract]   [Full Text] [Related]  

  • 20. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.
    Nagengast WB; Lub-de Hooge MN; Oosting SF; den Dunnen WF; Warnders FJ; Brouwers AH; de Jong JR; Price PM; Hollema H; Hospers GA; Elsinga PH; Hesselink JW; Gietema JA; de Vries EG
    Cancer Res; 2011 Jan; 71(1):143-53. PubMed ID: 21084271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.